Nascent Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Nascent Biotech has a total shareholder equity of $30.4K and total debt of $125.0K, which brings its debt-to-equity ratio to 411.6%. Its total assets and total liabilities are $641.3K and $610.9K respectively.
Key information
411.6%
Debt to equity ratio
US$125.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$623.85k |
| Equity | US$30.37k |
| Total liabilities | US$610.93k |
| Total assets | US$641.30k |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NBIO's short term assets ($641.3K) exceed its short term liabilities ($610.9K).
Long Term Liabilities: NBIO's short term assets ($641.3K) do not cover its long term liabilities ($-1.0).
Debt to Equity History and Analysis
Debt Level: NBIO has more cash than its total debt.
Reducing Debt: NBIO's debt to equity ratio has increased from 0% to 411.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NBIO has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NBIO is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.